Physician profile
Gerald E Manning
NPI 1083701858
$438.49
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $48.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113.01 | 2021 | |
| Lilly USA, LLC | $55.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.45 | 2021 | |
| Novo Nordisk INC | $33.45 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $25.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.68 | 2021 | |
| Astellas Pharma US INC | $21.72 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.30 | 2022 | |
| Merck Sharp & Dohme LLC | $19.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.19 | 2021 | |
| Amarin Pharma, INC. | $18.38 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.41 | 2021 | |
| Antares Pharma, INC. | $11.29 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.